NWSA vs SABSW · rev $9.03B vs P/E 0.0
NWSA (NWSA) versus SAB Biotherapeutics Inc (SABSW) — a side-by-side from cached financials, not a winner call.
NWSA (NWSA) common stock.
SAB Biotherapeutics Inc (SABSW) common stock listed on NASDAQ.
Latest reported NWSA revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 328.1% from 2025-06-30 to 2026-06-30. NWSA currently screens at market cap $0.
SABSW does not have a complete income-statement cache yet.
NWSA currently screens at market cap $0. SABSW currently screens at market cap $0 and trailing P/E 0.0.
Not investment advice. Open the NWSA and SABSW stock pages for the full models.
Not investment advice.